biomedicina slovenica

pr=Beex : 9

  1. Paridaens Robert J; Dirix LucY; Beex Louk V; Nooij Marianne; Cameron David A; Čufer Tanja; Piccart Martine J; Bogaerts Jan; Therasse Patrick
    Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
    2008 ►
  2. Paridaens R; Therasse P; Dirix L; Beex L; Piccart M; Cameron D; Čufer T; Roozendaal K; Nooij M; Mattiacci M-R
    First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC breast group
    2004 ►
  3. Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Čufer T; Lobelle JP; Mattiaci MR
    The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
    2004 ►
  4. Paridaens R; Therasse P; Dirix L; Beex L; Piccart MJ; Cameron D; Čufer T; Roozendael K; Nooy M; Mattiacci MR
    First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC clinical trials group
    2004 ►
  5. Paridaens R; Dirix L; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Duchateau L; Hamilton A; Lobelle JP; Piccart M
    Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
    2003 ►
  6. Paridaens R; Dirix L; Beex L; Nooij MN; Čufer T; Lohrisch C; Biganzoli L; van Hoorebeeck I; Duchateau L; Lobelle JP; Piccart M
    Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control
    2000 ►
  7. Awada A; Biganzoli L; Čufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
    2002 ►
  8. Dirix L; Piccart MJ; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
    Efficacy of and tolerance to Exemestane (E) versus Tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European orgnisation for the research and treatment of cancer (EORTC breast group) phase II trial with Pharmacia and Upjohn
    2001 ►
  9. Lohrisch C; Paridaens R; Dirix LY; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
    Adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European organization of research and treatment of cancer (Breast group) trial with Pharmacias' Upjohn
    2001 ►

New search      Comments      Top of page Institute for Biostatistics and Medical Informatics